Cambridge Cancer Genomics (CCG.ai) are on a mission to ensure that each patient has the right drug, at the right time, to beat their cancer. We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response.
We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.
Location: United Kingdom, England, Cambridge
Employees: 11-50
Founded date: 2017
Investors 7
Mentions in press and media 6
| Date | Title | Description | Source |
| 24.07.2019 | Could The NHS Really Sell Its Data For $12 Billion? | EY estimates that the value of the curated NHS dataset could be as much as £5 billion ($6.2 billion)... | forbes.com... |
| 13.12.2018 | Companies tracking mutations in cancer cells can provide a k... | Investors and entrepreneurs are beginning to bring new diagnostic tools to market that promise bette... | techcrunch... |
| 02.08.2018 | A different path to growth: VC Pi Campus invests in AI start... | “This is not the Silicon Valley of Italy. We are different” says serial entrepreneur and investor Ma... | eu-startup... |
| 26.01.2018 | Who made the shortlist for SXSW Accelerator pitch competitio... | Cambridge Cancer Genomics has developed blood tests to inform and support targeted cancer therapies.... | medcitynew... |
| 22.08.2017 | Cambridge Cancer Genomics offers a better way to gauge effec... | John Cassidy’s family has been at the forefront of cancer research for three generations now. The C... | techcrunch... |
| - | Who made the shortlist for SXSW Accelerator pitch competitio... | Each year at the SXSW Interactive festival in Austin, early stage companies across multiple industri... | medcitynew... |